Company Overview of Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. discovers and develops novel antibody-based drugs targeting receptor tyrosine kinases (RTK) for the treatment of cancer and other diseases. Its lead product candidate includes KTN3379, an antibody targeting the ErbB3 RTK, which is in Phase I clinical trials for adult patients with advanced solid tumors. The company is also developing KTN0158, a KIT RTK inhibitor for the treatment of neurofibromatosis type 1 and other inflammatory diseases; and KIT-ADC, an antibody drug conjugate for oncology treatment, as well as a range of research programs targeting RTKs. Kolltan Pharmaceuticals, Inc. was founded in 2007 and is based in New Haven, Connecticut.
300 George Street
New Haven, CT 06511
Founded in 2007
Key Executives for Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Kolltan Pharmaceuticals, Inc., please visit www.kolltan.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.